NRIX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Based on the investor's beginner status, long-term investment preference, and available capital, Nurix Therapeutics Inc (NRIX) is not a strong buy at the moment. While the technical indicators are mildly bullish and analysts maintain positive ratings, the lack of immediate catalysts, weak financial performance, and neutral sentiment from hedge funds and insiders suggest holding off on investment for now. The stock may be better suited for investors willing to wait for clearer growth signals or upcoming catalysts in 2026 and beyond.
The MACD is positive at 0.0739, suggesting mild bullish momentum. RSI is neutral at 51.666, indicating no overbought or oversold conditions. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), and the stock is trading near its pivot level of 16.69. Key resistance levels are at 17.415 and 17.864, with support at 15.964 and 15.515.
Analysts maintain positive ratings with price targets ranging from $28 to $35, indicating potential upside. Upcoming clinical trial updates and data releases in 2026 could act as catalysts.
Revenue dropped significantly by -66.12% YoY in Q1 2026, and the company remains unprofitable with a net income of -$87.17M. No recent news or congress trading data to indicate strong interest or momentum.
In Q1 2026, revenue dropped by -66.12% YoY to $6.25M. Net income improved by 54.70% YoY but remains negative at -$87.17M. EPS increased by 17.91% YoY to -0.79, and gross margin remains at 100%. Overall, financial performance is weak and does not support a strong buy case.
Analysts maintain Buy and Overweight ratings with price targets ranging from $28 to $35. They highlight the potential of the company's pipeline, particularly in chronic lymphocytic leukemia and other indications, but note the lack of significant catalysts in the near term.
